Scleraxis messenger ribonucleic acid is expressed in C2C12 myoblasts and its level is down-regulated by bone morphogenetic protein-2 (BMP2)

Ying Liu, Akira Nifuji, Masato Tamura, John M. Wozney, Eric N. Olson, Masaki Noda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We examined the mRNA expression of scleraxis, a non-myogenic helix- loop-helix type transcription factor in C2C12 myogenic cells. Scleraxis mRNA has been shown to be expressed in sclerotome and perichondrium of the embryos. We found that C2C12 cells express 1.2 kb scleraxis mRNA constitutively. Since BMP was reported to induce ectopic bone formation when implanted in muscle, we examined the effects of BMP on scleraxis expression. Scleraxis mRNA expression in C2C12 cells was suppressed by the treatment with BMP2. This suppression was observed at 200 ng/ml but not at the lower concentrations. BMP2 treatment suppressed scleraxis mRNA level within 24 h and lasted at least up to 48 h. Electrophoresis mobility shift assay showed that the proteins in the crude nuclear extracts prepared from C2C12 cells bound to an Scx-E-box sequence, CATGTG, which is preferentially recognized by scleraxis. This binding was competed out by 100-fold molar excess of cold Scx-E-box sequence but not by the one with mutations in the E-box. This band was supershifted by the addition of antiserum raised against scleraxis. BMP2 treatment suppressed the Scx-E binding activity in C2C12 cells. This suppression of the Scx-E-box binding activity was in parallel to the BMP2 suppression of the transcriptional activity of the Scx-E-CAT reporter gene transfected into C2C12 cells. These data indicated that although the default pathway for C2C12 cells is to differentiate into muscle cells, these cells do express non-myogenic transcription factor, scleraxis, whose expression is suppressed by BMP2.

Original languageEnglish (US)
Pages (from-to)66-74
Number of pages9
JournalJournal of Cellular Biochemistry
Volume67
Issue number1
DOIs
StatePublished - Oct 1 1997

Fingerprint

Bone Morphogenetic Protein 2
Myoblasts
RNA
Messenger RNA
E-Box Elements
Muscle
Transcription Factors
Electrophoresis
Immune Sera
Assays
Bone
Genes
Cells
Electrophoretic Mobility Shift Assay
Complex Mixtures
Reporter Genes
Osteogenesis
Muscle Cells
Embryonic Structures
Proteins

Keywords

  • BMP2
  • C2C12 myoblasts
  • HLH-type transcription factor
  • mRNA
  • Scleraxis

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Scleraxis messenger ribonucleic acid is expressed in C2C12 myoblasts and its level is down-regulated by bone morphogenetic protein-2 (BMP2). / Liu, Ying; Nifuji, Akira; Tamura, Masato; Wozney, John M.; Olson, Eric N.; Noda, Masaki.

In: Journal of Cellular Biochemistry, Vol. 67, No. 1, 01.10.1997, p. 66-74.

Research output: Contribution to journalArticle

@article{04d027a22d5d459097881c98447e4fb9,
title = "Scleraxis messenger ribonucleic acid is expressed in C2C12 myoblasts and its level is down-regulated by bone morphogenetic protein-2 (BMP2)",
abstract = "We examined the mRNA expression of scleraxis, a non-myogenic helix- loop-helix type transcription factor in C2C12 myogenic cells. Scleraxis mRNA has been shown to be expressed in sclerotome and perichondrium of the embryos. We found that C2C12 cells express 1.2 kb scleraxis mRNA constitutively. Since BMP was reported to induce ectopic bone formation when implanted in muscle, we examined the effects of BMP on scleraxis expression. Scleraxis mRNA expression in C2C12 cells was suppressed by the treatment with BMP2. This suppression was observed at 200 ng/ml but not at the lower concentrations. BMP2 treatment suppressed scleraxis mRNA level within 24 h and lasted at least up to 48 h. Electrophoresis mobility shift assay showed that the proteins in the crude nuclear extracts prepared from C2C12 cells bound to an Scx-E-box sequence, CATGTG, which is preferentially recognized by scleraxis. This binding was competed out by 100-fold molar excess of cold Scx-E-box sequence but not by the one with mutations in the E-box. This band was supershifted by the addition of antiserum raised against scleraxis. BMP2 treatment suppressed the Scx-E binding activity in C2C12 cells. This suppression of the Scx-E-box binding activity was in parallel to the BMP2 suppression of the transcriptional activity of the Scx-E-CAT reporter gene transfected into C2C12 cells. These data indicated that although the default pathway for C2C12 cells is to differentiate into muscle cells, these cells do express non-myogenic transcription factor, scleraxis, whose expression is suppressed by BMP2.",
keywords = "BMP2, C2C12 myoblasts, HLH-type transcription factor, mRNA, Scleraxis",
author = "Ying Liu and Akira Nifuji and Masato Tamura and Wozney, {John M.} and Olson, {Eric N.} and Masaki Noda",
year = "1997",
month = "10",
day = "1",
doi = "10.1002/(SICI)1097-4644(19971001)67:1<66::AID-JCB7>3.0.CO;2-U",
language = "English (US)",
volume = "67",
pages = "66--74",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Scleraxis messenger ribonucleic acid is expressed in C2C12 myoblasts and its level is down-regulated by bone morphogenetic protein-2 (BMP2)

AU - Liu, Ying

AU - Nifuji, Akira

AU - Tamura, Masato

AU - Wozney, John M.

AU - Olson, Eric N.

AU - Noda, Masaki

PY - 1997/10/1

Y1 - 1997/10/1

N2 - We examined the mRNA expression of scleraxis, a non-myogenic helix- loop-helix type transcription factor in C2C12 myogenic cells. Scleraxis mRNA has been shown to be expressed in sclerotome and perichondrium of the embryos. We found that C2C12 cells express 1.2 kb scleraxis mRNA constitutively. Since BMP was reported to induce ectopic bone formation when implanted in muscle, we examined the effects of BMP on scleraxis expression. Scleraxis mRNA expression in C2C12 cells was suppressed by the treatment with BMP2. This suppression was observed at 200 ng/ml but not at the lower concentrations. BMP2 treatment suppressed scleraxis mRNA level within 24 h and lasted at least up to 48 h. Electrophoresis mobility shift assay showed that the proteins in the crude nuclear extracts prepared from C2C12 cells bound to an Scx-E-box sequence, CATGTG, which is preferentially recognized by scleraxis. This binding was competed out by 100-fold molar excess of cold Scx-E-box sequence but not by the one with mutations in the E-box. This band was supershifted by the addition of antiserum raised against scleraxis. BMP2 treatment suppressed the Scx-E binding activity in C2C12 cells. This suppression of the Scx-E-box binding activity was in parallel to the BMP2 suppression of the transcriptional activity of the Scx-E-CAT reporter gene transfected into C2C12 cells. These data indicated that although the default pathway for C2C12 cells is to differentiate into muscle cells, these cells do express non-myogenic transcription factor, scleraxis, whose expression is suppressed by BMP2.

AB - We examined the mRNA expression of scleraxis, a non-myogenic helix- loop-helix type transcription factor in C2C12 myogenic cells. Scleraxis mRNA has been shown to be expressed in sclerotome and perichondrium of the embryos. We found that C2C12 cells express 1.2 kb scleraxis mRNA constitutively. Since BMP was reported to induce ectopic bone formation when implanted in muscle, we examined the effects of BMP on scleraxis expression. Scleraxis mRNA expression in C2C12 cells was suppressed by the treatment with BMP2. This suppression was observed at 200 ng/ml but not at the lower concentrations. BMP2 treatment suppressed scleraxis mRNA level within 24 h and lasted at least up to 48 h. Electrophoresis mobility shift assay showed that the proteins in the crude nuclear extracts prepared from C2C12 cells bound to an Scx-E-box sequence, CATGTG, which is preferentially recognized by scleraxis. This binding was competed out by 100-fold molar excess of cold Scx-E-box sequence but not by the one with mutations in the E-box. This band was supershifted by the addition of antiserum raised against scleraxis. BMP2 treatment suppressed the Scx-E binding activity in C2C12 cells. This suppression of the Scx-E-box binding activity was in parallel to the BMP2 suppression of the transcriptional activity of the Scx-E-CAT reporter gene transfected into C2C12 cells. These data indicated that although the default pathway for C2C12 cells is to differentiate into muscle cells, these cells do express non-myogenic transcription factor, scleraxis, whose expression is suppressed by BMP2.

KW - BMP2

KW - C2C12 myoblasts

KW - HLH-type transcription factor

KW - mRNA

KW - Scleraxis

UR - http://www.scopus.com/inward/record.url?scp=0030884479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030884479&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-4644(19971001)67:1<66::AID-JCB7>3.0.CO;2-U

DO - 10.1002/(SICI)1097-4644(19971001)67:1<66::AID-JCB7>3.0.CO;2-U

M3 - Article

C2 - 9328840

AN - SCOPUS:0030884479

VL - 67

SP - 66

EP - 74

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 1

ER -